<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">AIDS Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">AIDS Res Ther</journal-id><journal-title-group><journal-title>AIDS Research and Therapy</journal-title></journal-title-group><issn pub-type="epub">1742-6405</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12102844</article-id><article-id pub-id-type="publisher-id">751</article-id><article-id pub-id-type="doi">10.1186/s12981-025-00751-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Distribution of CCR5-Delta32, CCR2-64I, and SDF1-3&#x02019;A host genetic factors in HIV-infected and uninfected individuals in Luanda, Angola</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1232-0119</contrib-id><name><surname>Sebasti&#x000e3;o</surname><given-names>Cruz S.</given-names></name><address><email>cruzdossantos10@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Pimentel</surname><given-names>Victor</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Jandondo</surname><given-names>Domingos</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sebasti&#x000e3;o</surname><given-names>Joana M.K.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sacomboio</surname><given-names>Euclides</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Pingarilho</surname><given-names>Marta</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Brito</surname><given-names>Miguel</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Cassinela</surname><given-names>Edson Kuatelela</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>de Vasconcelos</surname><given-names>Jocelyne Neto</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Abecasis</surname><given-names>Ana B.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Morais</surname><given-names>Joana</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Centro Nacional de Investiga&#x000e7;&#x000e3;o Cient&#x000ed;fica (CNIC), Luanda, Angola </aff><aff id="Aff2"><label>2</label>Centro de Investiga&#x000e7;&#x000e3;o em Sa&#x000fa;de de Angola (CISA)|Instituto Nacional de Investiga&#x000e7;&#x000e3;o em Sa&#x000fa;de (INIS), Luanda, Angola </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02xankh89</institution-id><institution-id institution-id-type="GRID">grid.10772.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2151 1713</institution-id><institution>Global Health and Tropical Medicine, Associate Laboratory in Translation and Innovation Towards Global Health, </institution><institution>GHTM, LA-REAL, Instituto de Higiene e Medicina Tropical, IHMT, Universidade NOVA de Lisboa, UNL, </institution></institution-wrap>Rua da Junqueira 100, Lisboa, 1349-008 Portugal </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0057ag334</institution-id><institution-id institution-id-type="GRID">grid.442562.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0647 3773</institution-id><institution>Instituto de Ci&#x000ea;ncias da Sa&#x000fa;de (ICISA), </institution><institution>Universidade Agostinho Neto (UAN), </institution></institution-wrap>Luanda, Angola </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04ea70f07</institution-id><institution-id institution-id-type="GRID">grid.418858.8</institution-id><institution-id institution-id-type="ISNI">0000 0000 9084 0599</institution-id><institution>H&#x00026;TRC - Health &#x00026; Technology Research Center, ESTeSL - Escola Superior de Tecnologia da Sa&#x000fa;de, </institution><institution>Instituto Polit&#x000e9;cnico de Lisboa, </institution></institution-wrap>Lisbon, Portugal </aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>22</volume><elocation-id>54</elocation-id><history><date date-type="received"><day>16</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>14</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">The HIV/AIDS pandemic remains a public health concern. Studies on host genetic polymorphisms that confer resistance to HIV-1 infection or delay HIV disease progression are scarce in African countries. Herein, we investigate the proportion of the mutated phenotype of the AIDS-related polymorphisms CCR5-Delta32, CCR2-64I, and SDF1-3&#x02019;A in HIV-infected and uninfected individuals in Luanda, the capital of Angola, a sub-Saharan African country.</p></sec><sec><title>Methods</title><p id="Par2">This was a cross-sectional study conducted with 284 individuals, of whom 159 were HIV-negative and 125 were HIV-positive. The CCR5-Delta32, CCR2-64I, and SDF1-3&#x02032;A genotypes were detected by conventional PCR and visualised on 2% agarose gel. A Chi-square test determined the frequency of each genetic variant and was deemed significant when <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></sec><sec><title>Results</title><p id="Par3">The frequency of CCR5-Delta32, CCR2-64I, and SDF1-3&#x000a0;A was 0% (0/272), 60.2% (154/256), and 42.5% (114/268), respectively. CCR2-64I and SDF1-3&#x000a0;A polymorphisms were statistically related to HIV infection (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). Statistically significant was observed between ABO blood groups (<italic>p</italic>&#x02009;=&#x02009;0.006) and HIV-1 subtype (<italic>p</italic>&#x02009;=&#x02009;0.015) with CCR2-64I. Also, the age group (<italic>p</italic>&#x02009;=&#x02009;0.024) and RH blood group (<italic>p</italic>&#x02009;=&#x02009;0.018) were statistically related to the distribution of SDF1-3&#x000a0;A polymorphism.</p></sec><sec><title>Conclusions</title><p id="Par4">We found no CCR5-Delta32 allele, while CCR2-64I and SDF1-3&#x02019;A were found and presented a relationship with HIV infection, age, ABO/RH blood group, and HIV-1 subtypes. The observed associations of CCR2-64I and SDF1-3&#x02032;A with HIV underscore the urgent need for further multidisciplinary research, with potential implications for targeted prevention and public health strategies. Therefore, studies investigating biological and non-biological factors related to susceptibility to HIV infection and AIDS progression or death should be conducted in Angola.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>HIV</kwd><kwd>AIDS-related gene variants</kwd><kwd>Allelic frequency</kwd><kwd>Angola</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100005635</institution-id><institution>Funda&#x000e7;&#x000e3;o Calouste Gulbenkian</institution></institution-wrap></funding-source><award-id>ENVOLVE Ci&#x000ea;ncia PALOP program that funded the HITOLA project (Number 250466)</award-id><principal-award-recipient><name><surname>Sebasti&#x000e3;o</surname><given-names>Cruz S.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001871</institution-id><institution>Funda&#x000e7;&#x000e3;o para a Ci&#x000ea;ncia e a Tecnologia</institution></institution-wrap></funding-source><award-id>FCT MARVEL (PTDC/SAU-PUB/4018/2021), FCT GHTM-UID/04413/2020 and LA-REAL-LA/P/0117/2020.</award-id><award-id>FCT MARVEL (PTDC/SAU-PUB/4018/2021), FCT GHTM-UID/04413/2020 and LA-REAL-LA/P/0117/2020.</award-id><award-id>FCT MARVEL (PTDC/SAU-PUB/4018/2021), FCT GHTM-UID/04413/2020 and LA-REAL-LA/P/0117/2020.</award-id><principal-award-recipient><name><surname>Pimentel</surname><given-names>Victor</given-names></name><name><surname>Pingarilho</surname><given-names>Marta</given-names></name><name><surname>Abecasis</surname><given-names>Ana B.</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par5">The HIV/AIDS pandemic remains a significant and ongoing public health challenge with considerable global implications [<xref ref-type="bibr" rid="CR1">1</xref>]. To identify critical host factors that facilitate HIV replication, there has been increasing research into candidate genes associated with HIV infection and AIDS progression or death [<xref ref-type="bibr" rid="CR2">2</xref>]. Despite this progress, there is still a lack of extensive data on the distribution and prevalence of host genetic polymorphisms that may confer resistance to HIV-1 infection or delay the progression of HIV-related diseases in African populations [<xref ref-type="bibr" rid="CR3">3</xref>]. This knowledge gap is particularly significant in sub-Saharan Africa, where the burden of HIV/AIDS remains high. Therefore, investigating the allelic variations of important genetic polymorphisms, such as CCR5-Delta32, CCR2-64I, and SDF1-3&#x02032;A, as well as their distribution across populations, may provide crucial insights into the HIV-1 infection epidemiology, disease progression, and its clinical management [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par6">The CCR5-Delta32 mutation has attracted attention because of its association with resistance to HIV infection in individuals who are homozygous for the mutation (mt/mt) [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>], although other studies showed that some HIV individuals harbour the CCR5-&#x00394;32/&#x00394;32 genotype [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. CCR2-64I mutation, involving a valine-to-isoleucine substitution at position 64 of the CCR2 receptor, does not appear to affect initial susceptibility to HIV infection, individuals who are heterozygous (wt/mt) or homozygous (mt/mt) for this mutation tend to experience slower disease progression possibly due to delayed viral replication, with delayed onset of AIDS or prolonged survival [<xref ref-type="bibr" rid="CR10">10</xref>]. Individuals homozygous (mt/mt) for the SDF1-3&#x02032;A mutation, a polymorphism within the SDF1 gene, exhibit faster disease progression, suggesting a potential role for this genetic variant in accelerating HIV-1 pathogenesis [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par7">These AIDS-related genetic polymorphisms (ARGs) have been shown to modulate susceptibility to HIV-1 infection and/or progression to AIDS [<xref ref-type="bibr" rid="CR15">15</xref>]. However, the precise influence of these genetic variants on HIV susceptibility and disease progression remains controversial [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Given the complexity of these host genetic factors and their potential clinical implications, a better understanding of their distribution in diverse populations is crucial. Currently, there is no study published assessing the host genetic polymorphisms that confer resistance to HIV-1 infection or delay HIV disease progression in Angola. This study aimed to investigate the proportion of the mutated phenotype of the main AIDS-related polymorphisms, CCR5-Delta32, CCR2-64I, and SDF1-3&#x02032;A among HIV-infected and uninfected individuals in Luanda, the capital city of Angola, a country located in sub-Saharan Africa, in order to contribute to an understanding of the host genetic factors that influence HIV susceptibility and progression in this population and thus provide valuable information to adapt preventive and therapeutic strategies for the management of HIV/AIDS in Angola and similar regions in Africa.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design and setting</title><p id="Par8">This was a part of a larger cross-sectional study, in which 284 individuals were randomly selected for inclusion. Of which, 159 were HIV-negative and 125 HIV-positive selected at the National Blood Transfusion Service in Angola (NBTS), a reference health unit, located in Luanda, the capital city of Angola, between March to May 2022. We included adults, male or female, and all those recently diagnosed with HIV had not been exposed to ART. The study was conducted following Helsinki&#x02019;s Declaration. This study was approved by the National Ethics Committee of the Angolan Ministry of Health (nr. 39/2021, approved on 01 December 2021) and the direction board of the National Blood Transfusion Service (nr.128/GDG/INS/2022, approved on 24 February 2022). Participants were informed about the objectives of the study, and verbal informed consent was obtained from all enrolled participants even before they were considered part of the study.</p></sec><sec id="Sec4"><title>Data/sample collection and laboratory procedure</title><p id="Par9">All the participants were screened for anti-HIV (Abbott, USA) with the ARCHITECT Plus i2000sr (Abbott, USA), following the manufacturer&#x02019;s instructions. HIV-reactive and non-reactive participants were randomly selected and included in the test (HIV+) and control (HIV-) groups, respectively. HIV-1 viral load was determined using the Applied Biosystems m2000rt Real Time PCR Instrument, following the manufacturer&#x02019;s protocols. We used a questionnaire to collect sociodemographic data, such as age and gender, from the participants. Also, 5&#x000a0;ml of an intravenous whole blood sample was collected into tubes containing ethylenediaminetetraacetic acid (EDTA). ABO/Rh blood group phenotypes determination was carried out using blood reagents and diagnostic kits (Lorne Laboratories Limited, UK), following the manufacturer&#x02019;s instructions [<xref ref-type="bibr" rid="CR16">16</xref>]. HIV-1 genotyping and bioinformatic analysis were performed as described by Sebasti&#x000e3;o et al., 2024 [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. REGA [<xref ref-type="bibr" rid="CR19">19</xref>] and Comet [<xref ref-type="bibr" rid="CR20">20</xref>] genotyping tools were used to examine the HIV-1 genetic diversity. Calibrated Population Resistance (CPR) tool (<ext-link ext-link-type="uri" xlink:href="https://hivdb.stanford.edu/cpr/">https://hivdb.stanford.edu/cpr/</ext-link>) was used to calculate the proportions of individuals with NRTI, NNRTI, PI, and INSTI-associated resistance, considering the list published by Tzou et al., 2020 [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par10">Furthermore, blood samples were collected from all participants, spotted on DBS Whatman 903, and allowed to dry at room temperature.</p></sec><sec id="Sec5"><title>Genotyping using DBS samples</title><p id="Par11">DNA was extracted from DBS using the QIAamp DNA Mini Kit (Qiagen) following the manufacturer&#x02019;s instructions. The CCR5-Delta32, CCR2-64I and SDF1-3&#x02032;A genotypes were detected by conventional PCR with specific primers covering polymorphic sites of CCR5-Delta32 (forward&#x02013; 5&#x02032;-CTTCATCATCCTCCTGACAATCG&#x02010;3&#x02032; and reverse&#x02013; 5&#x02032;&#x02010;GACCAGCCCCAAGTTGACTATC&#x02010;3&#x02032;), SDF1-3&#x000a0;A (forward&#x02013; 5&#x02032;&#x02010;CAGTCAACCTGGGCAAAGCC&#x02010;3&#x02032; and reverse&#x02013; 5&#x02032;&#x02010;AGCTTTGGTCCTGAGAGTCC&#x02010;3&#x02032;), and CCR2-64I (forward&#x02013; 5&#x02032;&#x02010;GGATTGAACAAGGACGCATTTCCCC&#x02010;3&#x02032; and reverse&#x02013; 5&#x02032;&#x02010;TTGCACATTGCATTCCCAAAGACCC&#x02010;3&#x02032;) as described by Nkenfou et al., 2013 [<xref ref-type="bibr" rid="CR22">22</xref>]. For the PCR reaction, 5&#x000b5;L (ranging 1.5&#x02013;19ng) of extracted DNA was used in a mixture of a final volume of 20&#x000b5;L containing 12.5&#x000b5;L of GoTaq<sup>&#x000ae;</sup> Green Master Mix (PROMEGA) or NZYTaq II 2x Green Master Mix (NZYTECH), 2.5&#x000b5;L of forward primer, 2.5&#x000b5;L of reverse primer, and 2.5&#x000b5;L of ultrapure water. The mixture was run in a GeneAmp PCR System 2700/9700 thermocycler (Applied Biosystems) at 95&#x000a0;&#x000b0;C for 5&#x000a0;min followed by 35 cycles of 95&#x000a0;&#x000b0;C for 45&#x000a0;s, 58/63&#x000b0;C (annealing temperature) for 45&#x000a0;s, and 72&#x000a0;&#x000b0;C for 45&#x000a0;s, and a final extension of 72&#x000a0;&#x000b0;C for 10&#x000a0;min. The annealing temperature of 58&#x000a0;&#x000b0;C was the same for CCR5-Delta32, SDF1-3&#x000a0;A, while for the CCR2-64I gene, it was 63&#x000a0;&#x000b0;C. PCR products were visualised on 2% agarose gel. Primers CCR5-Delta32 produce a 262&#x000a0;bp fragment if the person does not have the mutation on both alleles (wild type), while CCR2-64I produces a 380&#x000a0;bp fragment and SDF1-3&#x000a0;A produces a 302&#x000a0;bp fragment.</p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par12">The analysis was conducted in SPSS version 29 (IBM SPSS Statistics, USA). The descriptive analysis was presented as frequencies and percentages. The differences in the frequency of each genetic variant between HIV-1 seronegative and HIV-1 seropositive groups, which were our dependent variables, were determined by a Chi-square or Fisher&#x02019;s exact test, when appropriate. A value of <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 was considered statistically significant.</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Distribution of CCR5-Delta32, CCR2-64I and SDF1-3&#x02019;A host molecular factors</title><p id="Par13">The demographic characterisation and distribution of host genetic factors CCR5-Delta32, CCR2-64I, and SDF1-3&#x02019;A related to HIV infection and progression are presented in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Of the 284 enrolled participants, 10.9% (31/284) were female, while 89.1% (253/284) were male. Ages ranged from 19 to 60 years old, with a mean of 33&#x000b1;9.4 years. The age group of 20 to 40 years was predominant with 75% (213/284), followed by participants over 40 years (22.2%, 63/284). Regarding HIV infection status, the population consisted of 159 (56%) HIV-negative and 125 (44%) HIV-positive. The frequency of CCR5-Delta32, CCR2-64I, and SDF1-3&#x000a0;A polymorphisms was 0% (0/272), 60.2% (154/256), and 42.5% (114/268), respectively. CCR2-64I and SDF1-3&#x000a0;A polymorphisms were statistically related to HIV infection (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). The presence of the CCR2-64I polymorphism in the heterozygous form (wt/mt) was 79.5% in HIV-uninfected individuals which corresponds to 3.9 times more than that observed in positive individuals, while in the homozygous form with the mutant allele (mt/mt), it was observed in 93.4% in HIV-uninfected individuals and only 6.3% in HIV-infected individuals, which corresponds to 14.9 times more than that observed in positive individuals (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). On the other hand, the SDF1-3&#x000a0;A polymorphism, whether in the heterozygous (wt/mt) or homozygous (mt/mt) form with the mutant allele, was more frequent in HIV-positive individuals (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). Among HIV-positive individuals, the proportion of SDF1-3&#x02032;A was approximately 37.7 times higher in the heterozygous form and about 10 times higher in the homozygous form, compared to HIV-negative individuals.</p><p id="Par14">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Distribution of CCR5-Delta32, CCR2-64I, and SDF1-3&#x02019;A host molecular factors in HIV-infected and uninfected individuals in Luanda, Angola</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Gene variants</th><th align="left" rowspan="2"><italic>N</italic> (%)</th><th align="left">Gender</th><th align="left"/><th align="left"/><th align="left">Age group</th><th align="left"/><th align="left"/><th align="left"/><th align="left">HIV status</th><th align="left"/><th align="left"/></tr><tr><th align="left">Female (%)</th><th align="left">Male (%)</th><th align="left"><italic>p</italic>-value</th><th align="left">&#x0003c;&#x02009;20 yrs (%)</th><th align="left">20&#x02013;40 yrs (%)</th><th align="left">&#x0003e;&#x02009;40 yrs (%)</th><th align="left"><italic>p</italic>-value</th><th align="left">Negative (%; 95% CI)</th><th align="left">Positive (%; 95% CI)</th><th align="left"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left">Overall</td><td align="left">284 (100)</td><td char="." align="char">31 (10.9)</td><td align="left">253 (89.1)</td><td align="left"/><td char="." align="char">8 (2.8)</td><td char="." align="char">213 (75.0)</td><td char="." align="char">63 (22.2)</td><td align="left"/><td char="." align="char">159 (56.0)</td><td char="." align="char">125 (44.0)</td><td align="left"/></tr><tr><td align="left">CCR5-Delta32 (%)</td><td align="left">272 (100)</td><td char="." align="char">29 (10.7)</td><td align="left">243 (89.3)</td><td align="left"/><td char="." align="char">8 (2.9)</td><td char="." align="char">205 (75.4)</td><td align="left"/><td align="left"/><td char="." align="char">147 (54.0; 45.9&#x02013;62.1)</td><td char="." align="char">125 (46.0; 37.3&#x02013;54.7)</td><td align="left"/></tr><tr><td align="left">&#x02003;wt/wt</td><td align="left">272 (100)</td><td char="." align="char">29 (10.7)</td><td align="left">243 (89.3)</td><td align="left">-</td><td char="." align="char">8 (2.9)</td><td char="." align="char">205 (75.4)</td><td char="." align="char">59 (21.7)</td><td align="left">-</td><td char="." align="char">147 (54.0; 45.9&#x02013;62.1)</td><td char="." align="char">125 (46.0)</td><td align="left">-</td></tr><tr><td align="left">&#x02003;wt/mt</td><td align="left">0 (0.0)</td><td char="." align="char">0 (0.0)</td><td align="left">0 (0.0)</td><td align="left"/><td char="." align="char">0 (0.0)</td><td char="." align="char">0 (0.0)</td><td char="." align="char">0 (0.0)</td><td align="left"/><td char="." align="char">0 (0.0)</td><td char="." align="char">0 (0.0)</td><td align="left"/></tr><tr><td align="left">&#x02003;mt/mt</td><td align="left">0 (0.0)</td><td char="." align="char">0 (0.0)</td><td align="left">0 (0.0)</td><td align="left"/><td char="." align="char">0 (0.0)</td><td char="." align="char">0 (0.0)</td><td char="." align="char">0 (0.0)</td><td align="left"/><td char="." align="char">0 (0.0)</td><td char="." align="char">0 (0.0)</td><td align="left"/></tr><tr><td align="left">CCR2-64I (%)</td><td align="left">256 (100)</td><td char="." align="char">28 (10.9)</td><td align="left">228 (89.1)</td><td align="left"/><td char="." align="char">8 (3.1)</td><td char="." align="char">189 (73.8)</td><td char="." align="char">59 (23.0)</td><td align="left"/><td char="." align="char">133 (52.0; 43.5&#x02013;60.5)</td><td char="." align="char">123 (48.0; 39.2&#x02013;56.8)</td><td align="left"/></tr><tr><td align="left">&#x02003;wt/wt</td><td align="left">102 (39.8)</td><td char="." align="char">12 (11.8)</td><td align="left">90 (88.2)</td><td align="left">0.922</td><td char="." align="char">1 (1.0)</td><td char="." align="char">75 (73.5)</td><td char="." align="char">26 (25.5)</td><td align="left">0.192</td><td char="." align="char">6 (5.9)</td><td char="." align="char">96 (94.1)</td><td align="left">
<bold>&#x0003c;&#x02009;0.001</bold>
</td></tr><tr><td align="left">&#x02003;wt/mt</td><td align="left">122 (47.7)</td><td char="." align="char">13 (10.7)</td><td align="left">109 (89.3)</td><td align="left"/><td char="." align="char">4 (3.3)</td><td char="." align="char">91 (74.6)</td><td char="." align="char">27 (22.1)</td><td align="left"/><td char="." align="char">97 (79.5)</td><td char="." align="char">25 (20.5)</td><td align="left"/></tr><tr><td align="left">&#x02003;mt/mt</td><td align="left">32 (12.5)</td><td char="." align="char">3 (9.4)</td><td align="left">29 (90.6)</td><td align="left"/><td char="." align="char">3 (9.4)</td><td char="." align="char">23 (71.9)</td><td char="." align="char">6 (18.8)</td><td align="left"/><td char="." align="char">30 (93.8)</td><td char="." align="char">2 (6.3)</td><td align="left"/></tr><tr><td align="left">SDF1-3&#x02032;A (%)</td><td align="left">268 (100)</td><td char="." align="char">29 (10.8)</td><td align="left">239 (89.2)</td><td align="left"/><td char="." align="char">7 (2.6)</td><td char="." align="char">201 (75.0)</td><td char="." align="char">60 (22.4)</td><td align="left"/><td char="." align="char">143 (53.4; 45.2&#x02013;61.6)</td><td char="." align="char">125 (46.6; 37.9&#x02013;55.3)</td><td align="left"/></tr><tr><td align="left">&#x02003;wt/wt</td><td align="left">154 (57.5)</td><td char="." align="char">16 (10.4)</td><td align="left">138 (89.6)</td><td align="left">0.391</td><td char="." align="char">6 (3.9)</td><td char="." align="char">114 (74.0)</td><td char="." align="char">34 (22.1)</td><td align="left">0.609</td><td char="." align="char">140 (97.9)</td><td char="." align="char">14 (11.2)</td><td align="left">
<bold>&#x0003c;&#x02009;0.001</bold>
</td></tr><tr><td align="left">&#x02003;wt/mt</td><td align="left">102 (38.1)</td><td char="." align="char">13 (12.7)</td><td align="left">89 (87.3)</td><td align="left"/><td char="." align="char">1 (1.0)</td><td char="." align="char">77 (75.5)</td><td char="." align="char">24 (23.5)</td><td align="left"/><td char="." align="char">3 (2.1)</td><td char="." align="char">99 (79.2)</td><td align="left"/></tr><tr><td align="left">&#x02003;mt/mt</td><td align="left">12 (4.5)</td><td char="." align="char">0 (0.0)</td><td align="left">12 (100)</td><td align="left"/><td char="." align="char">0 (0.0)</td><td char="." align="char">10 (83.3)</td><td char="." align="char">2 (16.7)</td><td align="left"/><td char="." align="char">0 (0.0)</td><td char="." align="char">12 (9.6)</td><td align="left"/></tr></tbody></table><table-wrap-foot><p>Note: wt, wild-type allele; mt, mutant allele. Bold numbers indicate statistical significance for the Chi-square (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05)</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec9"><title>Determinants related to CCR2-64I and SDF1-3&#x02019;A in HIV-infected individuals</title><p id="Par15">The determinants related to the distribution of polymorphisms in HIV-positive individuals are presented in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. The frequency of CCR2-64I polymorphism was 78% (96/123) wt/wt, 20.3% (25/123) wt/mt, and 1.6% (2/123) mt/mt. A statistically significant relationship was observed between ABO blood groups with the distribution of CCR2-64I polymorphism, with 50% of the polymorphism in the homozygous mutant form (mt/mt) observed in AB and O blood groups simultaneously (<italic>p</italic>&#x02009;=&#x02009;0.006). Furthermore, the distribution of HIV-1 subtypes into HIV-1&#x000a0;C and non-C was statistically related to the presence of the CCR2-64I polymorphism, with the HIV-1&#x000a0;C subtype being prevalent in heterozygous patients (wt/mt). In contrast, HIV-1 non-C subtypes were more frequent in homozygous patients with the presence of the allele (mt/mt) (<italic>p</italic>&#x02009;=&#x02009;0.015). On the other hand, the frequency of SDF1-3&#x000a0;A polymorphism was 11.2% (14/125) wt/wt, 79.2% (99/125) wt/mt, and 9.6% (12/125) mt/mt. A statistically significant relationship was observed between age groups with the distribution of SDF1-3&#x000a0;A polymorphism, with 83.3% of the polymorphism in the homozygous mutant form (mt/mt) observed in the age group of 20 to 40 years (<italic>p</italic>&#x02009;=&#x02009;0.024). Furthermore, the distribution of the RH blood group was statistically related to the presence of the SDF1-3&#x000a0;A polymorphism, with RH&#x02009;+&#x02009;being prevalent whether in heterozygotes (wt/mt) or homozygotes with the presence of the allele (mt/mt) (<italic>p</italic>&#x02009;=&#x02009;0.018).</p><p id="Par16">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Demographic, biological, and virologic determinants related to the distribution of host molecular factors CCR2-64I and SDF1-3&#x02019;A in HIV-infected individuals in Luanda, Angola</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Independent variables</th><th align="left" rowspan="2">
<bold>Overall (%)</bold>
</th><th align="left" colspan="4">CCR2-64I</th><th align="left" colspan="5">SDF1-3&#x02032;A</th></tr><tr><th align="left">wt/wt (%)</th><th align="left">wt/mt (%)</th><th align="left">mt/mt (%)</th><th align="left">p-value</th><th align="left">Overall (%)</th><th align="left">wt/wt (%)</th><th align="left">wt/mt (%)</th><th align="left">mt/mt (%)</th><th align="left"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left">Overall</td><td align="left">123 (100)</td><td align="left">96 (78.0)</td><td char="." align="char">25 (20.3)</td><td align="left">2 (1.6)</td><td align="left"/><td align="left">125 (100)</td><td char="." align="char">14 (11.2)</td><td align="left">99 (79.2)</td><td align="left">12 (9.6)</td><td align="left"/></tr><tr><td align="left">Age group (years)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;&#x0003c;20yrs</td><td align="left">3 (2.4)</td><td align="left">1 (1.0)</td><td char="." align="char">2 (8.0)</td><td align="left">0 (0.0)</td><td char="." align="char">0.27</td><td align="left">3 (2.4)</td><td char="." align="char">2 (14.3)</td><td align="left">1 (1.0)</td><td align="left">0 (0.0)</td><td char="." align="char">
<bold>0.024</bold>
</td></tr><tr><td align="left">&#x02003;20-40yrs</td><td align="left">93 (75.6)</td><td align="left">72 (75.0)</td><td char="." align="char">19 (76.0)</td><td align="left">2 (100)</td><td align="left"/><td align="left">95 (76.0)</td><td char="." align="char">11 (78.6)</td><td align="left">74 (74.7)</td><td align="left">10 (83.3)</td><td align="left"/></tr><tr><td align="left">&#x02003;&#x0003e;40yrs</td><td align="left">27 (22.0)</td><td align="left">23 (24.0)</td><td char="." align="char">4 (16.0)</td><td align="left">0 (0.0)</td><td align="left"/><td align="left">27 (21.6)</td><td char="." align="char">1 (7.1)</td><td align="left">24 (24.2)</td><td align="left">2 (16.7)</td><td align="left"/></tr><tr><td align="left">Gender</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;Female</td><td align="left">14 (11.4)</td><td align="left">12 (12.5)</td><td char="." align="char">2 (8.0)</td><td align="left">0 (0.0)</td><td char="." align="char">0.719</td><td align="left">14 (11.2)</td><td char="." align="char">1 (7.1)</td><td align="left">13 (13.1)</td><td align="left">0 (0.0)</td><td char="." align="char">0.347</td></tr><tr><td align="left">&#x02003;Male</td><td align="left">109 (88.6)</td><td align="left">84 (87.5)</td><td char="." align="char">23 (92.0)</td><td align="left">2 (100)</td><td align="left"/><td align="left">111 (88.8)</td><td char="." align="char">13 (92.9)</td><td align="left">86 (86.9)</td><td align="left">12 (100)</td><td align="left"/></tr><tr><td align="left">ABO blood group</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;A</td><td align="left">31 (25.2)</td><td align="left">29 (30.2)</td><td char="." align="char">2 (8.0)</td><td align="left">0 (0.0)</td><td char="." align="char">
<bold>0.006</bold>
</td><td align="left">31 (24.8)</td><td char="." align="char">1 (7.1)</td><td align="left">28 (28.3)</td><td align="left">2 (16.7)</td><td char="." align="char">0.337</td></tr><tr><td align="left">&#x02003;B</td><td align="left">27 (22.0)</td><td align="left">20 (20.8)</td><td char="." align="char">7 (28.0)</td><td align="left">0 (0.0)</td><td align="left"/><td align="left">28 (22.4)</td><td char="." align="char">6 (42.9)</td><td align="left">19 (19.2)</td><td align="left">3 (25.0)</td><td align="left"/></tr><tr><td align="left">&#x02003;AB</td><td align="left">5 (4.1)</td><td align="left">2 (2.1)</td><td char="." align="char">2 (8.0)</td><td align="left">1 (50.0)</td><td align="left"/><td align="left">5 (4.0)</td><td char="." align="char">1 (7.1)</td><td align="left">4 (4.0)</td><td align="left">0 (0.0)</td><td align="left"/></tr><tr><td align="left">&#x02003;O</td><td align="left">60 (48.8)</td><td align="left">45 (46.9)</td><td char="." align="char">14 (56.0)</td><td align="left">1 (50.0)</td><td align="left"/><td align="left">61 (48.8)</td><td char="." align="char">6 (42.9)</td><td align="left">48 (48.5)</td><td align="left">7 (58.3)</td><td align="left"/></tr><tr><td align="left">RH group</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;RH-</td><td align="left">1 (0.8)</td><td align="left">0 (0.0)</td><td char="." align="char">1 (4.0)</td><td align="left">0 (0.0)</td><td char="." align="char">0.139</td><td align="left">1 (0.8)</td><td char="." align="char">1 (7.1)</td><td align="left">0 (0.0)</td><td align="left">0 (0.0)</td><td char="." align="char">
<bold>0.018</bold>
</td></tr><tr><td align="left">&#x02003;RH+</td><td align="left">122 (99.2)</td><td align="left">96 (100)</td><td char="." align="char">24 (96.0)</td><td align="left">2 (100)</td><td align="left"/><td align="left">124 (99.2)</td><td char="." align="char">13 (92.9)</td><td align="left">99 (100)</td><td align="left">12 (12)</td><td align="left"/></tr><tr><td align="left">HIV-1 subtype</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;HIV-1C</td><td align="left">7 (22.6)</td><td align="left">3 (12.5)</td><td char="." align="char">4 (66.7)</td><td align="left">0 (0.0)</td><td char="." align="char">
<bold>0.015</bold>
</td><td align="left">7 (22.6)</td><td char="." align="char">3 (60.0)</td><td align="left">4 (17.4)</td><td align="left">0 (0.0)</td><td char="." align="char">0.073</td></tr><tr><td align="left">&#x02003;HIV-1 non-C</td><td align="left">24 (77.4)</td><td align="left">21 (87.5)</td><td char="." align="char">2 (33.3)</td><td align="left">1 (100)</td><td align="left"/><td align="left">24 (77.4)</td><td char="." align="char">2 (40.0)</td><td align="left">19 (82.6)</td><td align="left">3 (100)</td><td align="left"/></tr><tr><td align="left">Transmitted drug resistance</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;No</td><td align="left">22 (78.6)</td><td align="left">17 (77.3)</td><td char="." align="char">4 (80.0)</td><td align="left">1 (100)</td><td char="." align="char">0.86</td><td align="left">22 (78.6)</td><td char="." align="char">4 (80.0)</td><td align="left">15 (75.0)</td><td align="left">3 (100)</td><td char="." align="char">0.614</td></tr><tr><td align="left">&#x02003;Yes</td><td align="left">6 (21.4)</td><td align="left">5 (22.7)</td><td char="." align="char">1 (20.0)</td><td align="left">0 (0.0)</td><td align="left"/><td align="left">6 (21.4)</td><td char="." align="char">1 (20.0)</td><td align="left">5 (25.0)</td><td align="left">0 (0.0)</td><td align="left"/></tr><tr><td align="left">Viral load (Log<sub>10</sub>)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;&#x0003c;4</td><td align="left">5 (21.7)</td><td align="left">4 (23.5)</td><td char="." align="char">1 (20.0)</td><td align="left">0 (0.0)</td><td char="." align="char">0.352</td><td align="left">5 (21.7)</td><td char="." align="char">0 (0.0)</td><td align="left">5 (31.3)</td><td align="left">0 (0.0)</td><td char="." align="char">0.156</td></tr><tr><td align="left">&#x02003;4&#x02013;5</td><td align="left">10 (43.5)</td><td align="left">9 (52.9)</td><td char="." align="char">1 (20.0)</td><td align="left">0 (0.0)</td><td align="left"/><td align="left">10 (43.5)</td><td char="." align="char">1 (25.0)</td><td align="left">8 (50.0)</td><td align="left">1 (33.3)</td><td align="left"/></tr><tr><td align="left">&#x02003;&#x0003e;5</td><td align="left">8 (34.8)</td><td align="left">4 (23.5)</td><td char="." align="char">3 (60.0)</td><td align="left">1 (100)</td><td align="left"/><td align="left">8 (34.8)</td><td char="." align="char">3 (75.0)</td><td align="left">3 (18.8)</td><td align="left">2 (66.7)</td><td align="left"/></tr></tbody></table><table-wrap-foot><p>Note: wt, wild-type allele; mt, mutant allele. Bold numbers indicate statistical significance for the Chi-square (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05)</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec10"><title>Discussion</title><p id="Par17">To the best of our knowledge, this was the first study to describe the distribution of CCR5-Delta32, CCR2-64I, and SDF1-3&#x02032;A in the Angolan population as well as their relationship to HIV infection and progression to AIDS in Angola. Our analysis revealed the absence of the CCR5-Delta32 mutation in both HIV-negative and HIV-positive individuals in Luanda, the capital city of Angola, which might be a reflection of this allele frequency in the general population. Indeed, this mutation has been reported to exist principally at appreciable frequencies in Europe and western Asia but is low or even absent in Asians and/or Africans, which is consistent with our findings [<xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>].</p><p id="Par18">The CCR2-64I is common in most ethnic groups, including the African population [<xref ref-type="bibr" rid="CR26">26</xref>]. A frequency of 60.2% of the CCR2-64I mutation was found in the present study, which was high compared to that reported in African regions, around 31% [<xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref>]. Our results showed that the CCR2-64I mutation has a possible protective effect on HIV transmission in the Angolan population (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), with the heterozygous form (wt/mt) present in 80% of uninfected individuals compared to around 20% for infected individuals, while in the homozygous form (mt/mt), the mutation was present in 94% of uninfected individuals compared to 6% for infected individuals (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>), showing that the presence of the mutation may be playing an important role in the susceptibility to HIV infection in this population. Indeed, it was observed that 94% of wild-type individuals (wt/wt) had HIV infection compared to only 6% of wild-type individuals who did not have the infection. Furthermore, the CCR2-64I mutation was related to the ABO blood group, with individuals in groups AB and O being the most susceptible to presenting the mutation (<italic>p</italic>&#x02009;=&#x02009;0.006). Regarding HIV-1 subtypes, our findings indicate a statistically significant relationship (<italic>p</italic>&#x02009;=&#x02009;0.015) between the CCR2-64I mutation in the heterozygous form (wt/mt) with HIV-1-C (67%), while the homozygous form (mt/mt) with non-C subtypes (100%). It is also worth mentioning that, although without statistical significance (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05), 20% of the individuals who presented some transmitted resistance mutation, whether conferring resistance against PR, RT, or IN, presented the CCR2-64I mutation in the heterozygous form (wt/mt) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Also, high viral load values (&#x0003e;&#x02009;5Log<sub>10</sub>) were observed among HIV patients with heterozygous (60%) or homozygous (100%). Therefore, our results are consistent with the hypothesis that CCR2-64I alleles can delay HIV disease progression [<xref ref-type="bibr" rid="CR27">27</xref>] without affecting susceptibility to infection, which agrees with what was reported by Ma et al., 2005 [<xref ref-type="bibr" rid="CR29">29</xref>]. Contrary to what was observed in our study, a meta-analysis based on published studies on CCR2-64I regarding susceptibility to HIV infection concluded that this allele does not affect the risk of HIV-1 infection [<xref ref-type="bibr" rid="CR30">30</xref>]. This discrepancy in the scientific literature shows that further studies should be conducted to verify the role of the CCR2-64I mutation in susceptibility to HIV infection, AIDS progression, and/or mortality in people living with HIV in Africa.</p><p id="Par19">We observed a frequency of 43% of the SDF1-3&#x000a0;A mutation, below that observed worldwide, around 71%, but it is higher than that reported in other African countries, around 9% [<xref ref-type="bibr" rid="CR31">31</xref>]. Also, our result is below that observed in the West Region of Cameroon (100%) [<xref ref-type="bibr" rid="CR22">22</xref>]. Our results showed that the SDF1-3&#x02019;A mutation has an effect on HIV transmission in the Angolan population (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), with the heterozygous form (wt/mt) increasing the frequency from 2 to 79% in uninfected individuals to infected individuals, respectively, while in the homozygous form (mt/mt) it increases from 0 to 10% in uninfected individuals to infected individuals, respectively (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Furthermore, although not statistically significant, our findings seem to indicate a relationship between the SDF1-3&#x000a0;A mutation and non-C HIV-1 subtypes, since they were present in 83% of the heterozygous form (wt/mt) and 100% in the homozygous form (mt/mt). It is also worth mentioning that 25% of the individuals who presented some transmitted resistance mutation, whether conferring resistance against PR, RT, or IN, presented the SDF1-3&#x000a0;A mutation in the heterozygous form (wt/mt).</p><p id="Par20">Also, high viral load values (&#x0003e;&#x02009;5Log<sub>10</sub>) were observed among HIV patients with wild-type (75%) compared to heterozygous (19%) or homozygous (67%) patients (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Our results differ from those observed by Ma et al., 2005, who reported that SDF1-3&#x02019;A did not differ between HIV-seropositive and HIV-seronegative individuals from Cameroon [<xref ref-type="bibr" rid="CR29">29</xref>].</p><p id="Par21">Our study highlights the possible genetic factors present in the population that have played a crucial role in the susceptibility and progression of AIDS. However, the study does not present data on the relationship of these CCR2-64I and SDF1-3&#x000a0;A mutations with mortality, clinical profile or distribution of defence cells, or other important biological functions that define AIDS. The three genes (CCR5-Delta32, CCR2-64I, and SDF1-3&#x02032;A) were not typed in all 284 participants due to technical challenges encountered during the assays, such as poor DNA quality or insufficient DNA quantity in some samples, which limited the successful amplification and analysis of certain genetic markers, despite repeated attempts. It is worth mentioning that several factors, such as host susceptibility, genetics and immune function, access to health care, coinfections, nutritional status, and viral genetic variability, can affect the susceptibility to HIV infection as well as the rate of progression and death from AIDS [<xref ref-type="bibr" rid="CR32">32</xref>]. Therefore, future studies to analyse these distinct biological and non-biological factors that may explain the susceptibility to HIV infection and AIDS progression should be conducted with a large sample size in the Angolan population.</p></sec><sec id="Sec11"><title>Conclusion</title><p id="Par22">We investigated CCR5-Delta32, CCR2-64I, and SDF1-3&#x02019;A genetic polymorphisms in HIV-infected and uninfected individuals from Angola, a sub-Saharan African country. As expected, we found no CCR5-Delta32 mutation. On the other hand, CCR2-64I and SDF1-3&#x02019;A were found and presented a relationship with HIV infection, age, ABO/Rh blood group, and HIV-1 subtypes. Further studies investigating biological and non-biological factors related to susceptibility to HIV infection and AIDS progression or death should be conducted in Angola.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Ana B. Abecasis and Joana Morais contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors are grateful to all study participants. Thanks to the CNIC/CISA/INIS research team for the data collection, laboratory procedure, and technical/administrative support. The Funda&#x000e7;&#x000e3;o Calouste Gulbenkian (FCG) supported the present project financially under the ENVOLVE Ci&#x000ea;ncia PALOP program that funded the HITOLA project.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Conceptualisation: CSS. Data curation: CSS. Formal analysis: CSS. Funding acquisition: CSS. Methodology: CSS. Investigation: CSS, DJ, JMKS, ES, MB, EKC, JNV, ABA, VP, and JM. Project administration: CSS. Supervision: CSS. Validation: CSS. Writing&#x02013; original draft: CSS. Writing&#x02013; review &#x00026; editing: CSS, ES, and JM. All authors have seen and approved the submitted version of this manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This research was funded by the Funda&#x000e7;&#x000e3;o Calouste Gulbenkian (FCG), under the ENVOLVE Ci&#x000ea;ncia PALOP program that funded the HITOLA project (Number 250466), FCT MARVEL (PTDC/SAU-PUB/4018/2021), FCT GHTM-UID/04413/2020 and LA-REAL-LA/P/0117/2020.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par23">The study was conducted following Helsinki&#x02019;s Declaration. This study was approved by the National Ethics Committee of the Angolan Ministry of Health (nr. 39/2021, approved on 01 December 2021) and the direction board of the National Blood Transfusion Service (nr.128/GDG/INS/2022, approved on 24 February 2022). Participants were informed about the objectives of the study, and verbal informed consent was obtained from all enrolled participants even before they were considered part of the study.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par24">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par25">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">WHO. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022&#x02013;2030. [cited 15 Mar 2024]. Available: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/i/item/9789240053779">https://www.who.int/publications/i/item/9789240053779</ext-link></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Silva MJA, Marinho RL, dos Santos PAS, dos Santos CS, Ribeiro LR, Rodrigues YC et al. The Association between CCL5/RANTES SNPs and Susceptibility to HIV-1 Infection: A Meta-Analysis. Viruses. 2023;15: 1958. 10.3390/v15091958</mixed-citation></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Brien</surname><given-names>SJ</given-names></name><name><surname>Moore</surname><given-names>JP</given-names></name></person-group><article-title>The effect of genetic variation in chemokines and their receptorson HIV transmission and progression to AIDS</article-title><source>Immunol Rev</source><year>2000</year><volume>177</volume><fpage>99</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1034/j.1600-065X.2000.17710.x</pub-id><pub-id pub-id-type="pmid">11138790</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">O&#x02019;Brien SJ, Moore JP. The effect of genetic variation in chemokines and their receptorson HIV transmission and progression to AIDS. Immunol Rev. 2000;177:99&#x02013;111. 10.1034/j.1600-065X.2000.17710.x.<pub-id pub-id-type="pmid">11138790</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Hendrickson</surname><given-names>SL</given-names></name><name><surname>Jacobson</surname><given-names>LP</given-names></name><name><surname>Nelson</surname><given-names>GW</given-names></name><name><surname>Phair</surname><given-names>JP</given-names></name><name><surname>Lautenberger</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>RC</given-names></name><etal/></person-group><article-title>Host genetic influences on highly active antiretroviral therapy efficacy and AIDS-Free survival</article-title><source>JAIDS J Acquir Immune Defic Syndr</source><year>2008</year><volume>48</volume><fpage>263</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1097/QAI.0b013e31816fdc5f</pub-id><pub-id pub-id-type="pmid">18391751</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Hendrickson SL, Jacobson LP, Nelson GW, Phair JP, Lautenberger J, Johnson RC, et al. Host genetic influences on highly active antiretroviral therapy efficacy and AIDS-Free survival. JAIDS J Acquir Immune Defic Syndr. 2008;48:263&#x02013;71. 10.1097/QAI.0b013e31816fdc5f.<pub-id pub-id-type="pmid">18391751</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>DH</given-names></name><name><surname>Choi</surname><given-names>B-S</given-names></name><name><surname>Kim</surname><given-names>SS</given-names></name></person-group><article-title>The effects of rantes/CCR5 promoter polymorphisms on HIV disease progression in HIV-infected Koreans</article-title><source>Int J Immunogenet</source><year>2008</year><volume>35</volume><fpage>101</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1111/j.1744-313X.2007.00743.x</pub-id><pub-id pub-id-type="pmid">18218038</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Jang DH, Choi B-S, Kim SS. The effects of rantes/CCR5 promoter polymorphisms on HIV disease progression in HIV-infected Koreans. Int J Immunogenet. 2008;35:101&#x02013;5. 10.1111/j.1744-313X.2007.00743.x.<pub-id pub-id-type="pmid">18218038</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Jlizi</surname><given-names>A</given-names></name><name><surname>Edouard</surname><given-names>J</given-names></name><name><surname>Fadhlaoui-Zid</surname><given-names>K</given-names></name><name><surname>Frigi</surname><given-names>S</given-names></name><name><surname>Debr&#x000e9;</surname><given-names>P</given-names></name><name><surname>Slim</surname><given-names>A</given-names></name><etal/></person-group><article-title>Identification of the CCR5-&#x02206;32 HIV resistance allele and new mutations of the CCR5 gene in different Tunisian populations</article-title><source>Hum Immunol</source><year>2007</year><volume>68</volume><fpage>993</fpage><lpage>1000</lpage><pub-id pub-id-type="doi">10.1016/j.humimm.2007.10.003</pub-id><pub-id pub-id-type="pmid">18191728</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Jlizi A, Edouard J, Fadhlaoui-Zid K, Frigi S, Debr&#x000e9; P, Slim A, et al. Identification of the CCR5-&#x02206;32 HIV resistance allele and new mutations of the CCR5 gene in different Tunisian populations. Hum Immunol. 2007;68:993&#x02013;1000. 10.1016/j.humimm.2007.10.003.<pub-id pub-id-type="pmid">18191728</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Salem</surname><given-names>A-H</given-names></name><name><surname>Batzer</surname><given-names>MA</given-names></name></person-group><article-title>Distribution of the HIV resistance CCR5-&#x02206;32 allele among Egyptians and Syrians</article-title><source>Mutat Research/Fundamental Mol Mech Mutagen</source><year>2007</year><volume>616</volume><fpage>175</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.mrfmmm.2006.11.024</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Salem A-H, Batzer MA. Distribution of the HIV resistance CCR5-&#x02206;32 allele among Egyptians and Syrians. Mutat Research/Fundamental Mol Mech Mutagen. 2007;616:175&#x02013;80. 10.1016/j.mrfmmm.2006.11.024.</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Biti</surname><given-names>R</given-names></name><name><surname>Ffrench</surname><given-names>R</given-names></name><name><surname>Young</surname><given-names>J</given-names></name><name><surname>Bennetts</surname><given-names>B</given-names></name><name><surname>Stewart</surname><given-names>G</given-names></name><name><surname>Liang</surname><given-names>T</given-names></name></person-group><article-title>HIV-1 infection in an individual homozygous for the CCR5 deletion allele</article-title><source>Nat Med</source><year>1997</year><volume>3</volume><fpage>252</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1038/nm0397-252</pub-id><pub-id pub-id-type="pmid">9055842</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Biti R, Ffrench R, Young J, Bennetts B, Stewart G, Liang T. HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nat Med. 1997;3:252&#x02013;3. 10.1038/nm0397-252.<pub-id pub-id-type="pmid">9055842</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Balotta</surname><given-names>C</given-names></name><name><surname>Bagnarelli</surname><given-names>P</given-names></name><name><surname>Violin</surname><given-names>M</given-names></name><name><surname>Ridolfo</surname><given-names>AL</given-names></name><name><surname>Zhou</surname><given-names>D</given-names></name><name><surname>Berlusconi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient</article-title><source>AIDS</source><year>1997</year><volume>11</volume><fpage>F67</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1097/00002030-199710000-00001</pub-id><pub-id pub-id-type="pmid">9256936</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Balotta C, Bagnarelli P, Violin M, Ridolfo AL, Zhou D, Berlusconi A, et al. Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS. 1997;11:F67&#x02013;71. 10.1097/00002030-199710000-00001.<pub-id pub-id-type="pmid">9256936</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Mulherin</surname><given-names>SA</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>TR</given-names></name><name><surname>Ioannidis</surname><given-names>JP</given-names></name><name><surname>Goedert</surname><given-names>JJ</given-names></name><name><surname>Buchbinder</surname><given-names>SP</given-names></name><name><surname>Coutinho</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Effects of CCR5-&#x02206;32 and CCR2-64I alleles on HIV-1 disease progression</article-title><source>AIDS</source><year>2003</year><volume>17</volume><fpage>377</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1097/00002030-200302140-00012</pub-id><pub-id pub-id-type="pmid">12556692</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Mulherin SA, O&#x02019;Brien TR, Ioannidis JP, Goedert JJ, Buchbinder SP, Coutinho RA, et al. Effects of CCR5-&#x02206;32 and CCR2-64I alleles on HIV-1 disease progression. AIDS. 2003;17:377&#x02013;87. 10.1097/00002030-200302140-00012.<pub-id pub-id-type="pmid">12556692</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Tiensiwakul</surname><given-names>P</given-names></name></person-group><article-title>Stromal Cell-Derived factor (SDF) 1&#x02013;3&#x02032;A polymorphism May play a role in resistance to HIV-1 infection in seronegative High-Risk Thais</article-title><source>Intervirology</source><year>2004</year><volume>47</volume><fpage>87</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1159/000077831</pub-id><pub-id pub-id-type="pmid">15192272</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Tiensiwakul P. Stromal Cell-Derived factor (SDF) 1&#x02013;3&#x02032;A polymorphism May play a role in resistance to HIV-1 infection in seronegative High-Risk Thais. Intervirology. 2004;47:87&#x02013;92. 10.1159/000077831.<pub-id pub-id-type="pmid">15192272</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Winkler C, Modi W, Smith MW, Nelson GW, Wu X, Carrington M et al. Genetic Restriction of AIDS Pathogenesis by an SDF-1 Chemokine Gene Variant. Science (1979). 1998;279: 389&#x02013;393. 10.1126/science.279.5349.389</mixed-citation></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>van Rij</surname><given-names>RP</given-names></name><name><surname>Broersen</surname><given-names>S</given-names></name><name><surname>Goudsmit</surname><given-names>J</given-names></name><name><surname>Coutinho</surname><given-names>RA</given-names></name><name><surname>Schuitemaker</surname><given-names>H</given-names></name></person-group><article-title>The role of a stromal cell-derived factor-1 chemokine gene variant in the clinical course of HIV-1 infection</article-title><source>AIDS</source><year>1998</year><volume>12</volume><fpage>F85</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1097/00002030-199809000-00002</pub-id><pub-id pub-id-type="pmid">9662191</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">van Rij RP, Broersen S, Goudsmit J, Coutinho RA, Schuitemaker H. The role of a stromal cell-derived factor-1 chemokine gene variant in the clinical course of HIV-1 infection. AIDS. 1998;12:F85&#x02013;90.<pub-id pub-id-type="pmid">9662191</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Ioannidis</surname><given-names>JPA</given-names></name></person-group><article-title>Effects of CCR5-&#x02206; 32, CCR2-64I, and SDF-1 3&#x02032;A alleles on HIV-1 disease progression: an international Meta-Analysis of Individual-Patient data</article-title><source>Ann Intern Med</source><year>2001</year><volume>135</volume><fpage>782</fpage><pub-id pub-id-type="doi">10.7326/0003-4819-135-9-200111060-00008</pub-id><pub-id pub-id-type="pmid">11694103</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Ioannidis JPA. Effects of CCR5-&#x02206; 32, CCR2-64I, and SDF-1 3&#x02032;A alleles on HIV-1 disease progression: an international Meta-Analysis of Individual-Patient data. Ann Intern Med. 2001;135:782. 10.7326/0003-4819-135-9-200111060-00008.<pub-id pub-id-type="pmid">11694103</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Reiche</surname><given-names>V</given-names></name><name><surname>Bonametti</surname><given-names>E</given-names></name><name><surname>Voltarelli</surname><given-names>A</given-names></name><name><surname>Morimoto</surname><given-names>J</given-names></name><name><surname>Watanabe</surname><given-names>HE</given-names></name></person-group><article-title>Genetic polymorphisms in the chemokine and chemokine receptors: impact on clinical course and therapy of the human immunodeficiency virus type 1 infection (HIV-1)</article-title><source>Curr Med Chem</source><year>2007</year><volume>14</volume><fpage>1325</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.2174/092986707780597934</pub-id><pub-id pub-id-type="pmid">17504215</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Reiche V, Bonametti E, Voltarelli A, Morimoto J, Watanabe HE. Genetic polymorphisms in the chemokine and chemokine receptors: impact on clinical course and therapy of the human immunodeficiency virus type 1 infection (HIV-1). Curr Med Chem. 2007;14:1325&#x02013;34. 10.2174/092986707780597934.<pub-id pub-id-type="pmid">17504215</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Lorne Laboratories. Blood Reagents and Diagnostic Kits. Lorne Laboratories. 2018.</mixed-citation></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Sebasti&#x000e3;o</surname><given-names>CS</given-names></name><name><surname>Abecasis</surname><given-names>AB</given-names></name><name><surname>Jandondo</surname><given-names>D</given-names></name><name><surname>Sebasti&#x000e3;o</surname><given-names>JMK</given-names></name><name><surname>Vig&#x000e1;rio</surname><given-names>J</given-names></name><name><surname>Comandante</surname><given-names>F</given-names></name><etal/></person-group><article-title>HIV-1 diversity and pre-treatment drug resistance in the era of integrase inhibitor among newly diagnosed ART-na&#x000ef;ve adult patients in Luanda</article-title><source>Angola Sci Rep</source><year>2024</year><volume>14</volume><fpage>15893</fpage><pub-id pub-id-type="doi">10.1038/s41598-024-66905-1</pub-id><pub-id pub-id-type="pmid">38987263</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Sebasti&#x000e3;o CS, Abecasis AB, Jandondo D, Sebasti&#x000e3;o JMK, Vig&#x000e1;rio J, Comandante F, et al. HIV-1 diversity and pre-treatment drug resistance in the era of integrase inhibitor among newly diagnosed ART-na&#x000ef;ve adult patients in Luanda. Angola Sci Rep. 2024;14:15893. 10.1038/s41598-024-66905-1.<pub-id pub-id-type="pmid">38987263</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Sebasti&#x000e3;o</surname><given-names>CS</given-names></name><name><surname>Pingarilho</surname><given-names>M</given-names></name><name><surname>Bathy</surname><given-names>J</given-names></name><name><surname>Bonfim</surname><given-names>E</given-names></name><name><surname>Toancha</surname><given-names>K</given-names></name><name><surname>Miranda</surname><given-names>MNS</given-names></name><etal/></person-group><article-title>MARVEL-minimising the emergence and dissemination of HIV-1 drug resistance in Portuguese-speaking African countries (PALOP): low-cost portable NGS platform for HIV-1 surveillance in Africa</article-title><source>BMC Infect Dis</source><year>2024</year><volume>24</volume><fpage>884</fpage><pub-id pub-id-type="doi">10.1186/s12879-024-09803-1</pub-id><pub-id pub-id-type="pmid">39210296</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Sebasti&#x000e3;o CS, Pingarilho M, Bathy J, Bonfim E, Toancha K, Miranda MNS, et al. MARVEL-minimising the emergence and dissemination of HIV-1 drug resistance in Portuguese-speaking African countries (PALOP): low-cost portable NGS platform for HIV-1 surveillance in Africa. BMC Infect Dis. 2024;24:884. 10.1186/s12879-024-09803-1.<pub-id pub-id-type="pmid">39210296</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Pineda-Pe&#x000f1;a</surname><given-names>AC</given-names></name><name><surname>Faria</surname><given-names>NR</given-names></name><name><surname>Imbrechts</surname><given-names>S</given-names></name><name><surname>Libin</surname><given-names>P</given-names></name><name><surname>Abecasis</surname><given-names>AB</given-names></name><name><surname>Deforche</surname><given-names>K</given-names></name><etal/></person-group><article-title>Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools</article-title><source>Infect Genet Evol</source><year>2013</year><volume>19</volume><fpage>337</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2013.04.032</pub-id><pub-id pub-id-type="pmid">23660484</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Pineda-Pe&#x000f1;a AC, Faria NR, Imbrechts S, Libin P, Abecasis AB, Deforche K, et al. Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools. Infect Genet Evol. 2013;19:337&#x02013;48. 10.1016/j.meegid.2013.04.032.<pub-id pub-id-type="pmid">23660484</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Struck</surname><given-names>D</given-names></name><name><surname>Lawyer</surname><given-names>G</given-names></name><name><surname>Ternes</surname><given-names>A-M</given-names></name><name><surname>Schmit</surname><given-names>J-C</given-names></name><name><surname>Bercoff</surname><given-names>DP</given-names></name></person-group><article-title>COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification</article-title><source>Nucleic Acids Res</source><year>2014</year><volume>42</volume><fpage>e144</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1093/nar/gku739</pub-id><pub-id pub-id-type="pmid">25120265</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Struck D, Lawyer G, Ternes A-M, Schmit J-C, Bercoff DP. COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification. Nucleic Acids Res. 2014;42:e144&#x02013;144. 10.1093/nar/gku739.<pub-id pub-id-type="pmid">25120265</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Tzou</surname><given-names>PL</given-names></name><name><surname>Rhee</surname><given-names>S-Y</given-names></name><name><surname>Descamps</surname><given-names>D</given-names></name><name><surname>Clutter</surname><given-names>DS</given-names></name><name><surname>Hare</surname><given-names>B</given-names></name><name><surname>Mor</surname><given-names>O</given-names></name><etal/></person-group><article-title>Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance</article-title><source>J Antimicrob Chemother</source><year>2020</year><volume>75</volume><fpage>170</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1093/jac/dkz417</pub-id><pub-id pub-id-type="pmid">31617907</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Tzou PL, Rhee S-Y, Descamps D, Clutter DS, Hare B, Mor O, et al. Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance. J Antimicrob Chemother. 2020;75:170&#x02013;82. 10.1093/jac/dkz417.<pub-id pub-id-type="pmid">31617907</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Nkenfou</surname><given-names>CN</given-names></name><name><surname>Mekue</surname><given-names>LCM</given-names></name><name><surname>Nana</surname><given-names>CT</given-names></name><name><surname>Kuiate</surname><given-names>JR</given-names></name></person-group><article-title>Distribution of CCR5-Delta32, CCR5 promoter 59029 A/G, CCR2-64I and SDF1-3&#x02019;A genetic polymorphisms in HIV-1 infected and uninfected patients in the West region of Cameroon</article-title><source>BMC Res Notes</source><year>2013</year><volume>6</volume><fpage>288</fpage><pub-id pub-id-type="doi">10.1186/1756-0500-6-288</pub-id><pub-id pub-id-type="pmid">23880174</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Nkenfou CN, Mekue LCM, Nana CT, Kuiate JR. Distribution of CCR5-Delta32, CCR5 promoter 59029 A/G, CCR2-64I and SDF1-3&#x02019;A genetic polymorphisms in HIV-1 infected and uninfected patients in the West region of Cameroon. BMC Res Notes. 2013;6:288. 10.1186/1756-0500-6-288.<pub-id pub-id-type="pmid">23880174</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Sabeti</surname><given-names>PC</given-names></name><name><surname>Walsh</surname><given-names>E</given-names></name><name><surname>Schaffner</surname><given-names>SF</given-names></name><name><surname>Varilly</surname><given-names>P</given-names></name><name><surname>Fry</surname><given-names>B</given-names></name><name><surname>Hutcheson</surname><given-names>HB</given-names></name><etal/></person-group><article-title>The case for selection at CCR5-&#x02206;32</article-title><source>PLoS Biol</source><year>2005</year><volume>3</volume><fpage>e378</fpage><pub-id pub-id-type="doi">10.1371/journal.pbio.0030378</pub-id><pub-id pub-id-type="pmid">16248677</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Sabeti PC, Walsh E, Schaffner SF, Varilly P, Fry B, Hutcheson HB, et al. The case for selection at CCR5-&#x02206;32. PLoS Biol. 2005;3:e378. 10.1371/journal.pbio.0030378.<pub-id pub-id-type="pmid">16248677</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Galvani</surname><given-names>AP</given-names></name><name><surname>Novembre</surname><given-names>J</given-names></name></person-group><article-title>The evolutionary history of the CCR5-&#x02206;32 HIV-resistance mutation</article-title><source>Microbes Infect</source><year>2005</year><volume>7</volume><fpage>302</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2004.12.006</pub-id><pub-id pub-id-type="pmid">15715976</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Galvani AP, Novembre J. The evolutionary history of the CCR5-&#x02206;32 HIV-resistance mutation. Microbes Infect. 2005;7:302&#x02013;9. 10.1016/j.micinf.2004.12.006.<pub-id pub-id-type="pmid">15715976</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Novembre</surname><given-names>J</given-names></name><name><surname>Galvani</surname><given-names>AP</given-names></name><name><surname>Slatkin</surname><given-names>M</given-names></name></person-group><article-title>The geographic spread of the CCR5 &#x02206;32 HIV-Resistance allele</article-title><source>PLoS Biol</source><year>2005</year><volume>3</volume><fpage>e339</fpage><pub-id pub-id-type="doi">10.1371/journal.pbio.0030339</pub-id><pub-id pub-id-type="pmid">16216086</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Novembre J, Galvani AP, Slatkin M. The geographic spread of the CCR5 &#x02206;32 HIV-Resistance allele. PLoS Biol. 2005;3:e339. 10.1371/journal.pbio.0030339.<pub-id pub-id-type="pmid">16216086</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science (1979). 1997;277: 959&#x02013;965. 10.1126/science.277.5328.959</mixed-citation></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Anzala</surname><given-names>A</given-names></name><name><surname>Ball</surname><given-names>T</given-names></name><name><surname>Rostron</surname><given-names>T</given-names></name><name><surname>Os&#x02019;Brien</surname><given-names>S</given-names></name><name><surname>Plummer</surname><given-names>F</given-names></name><name><surname>Rowland-Jones</surname><given-names>S</given-names></name></person-group><article-title>CCR2-64I allele and genotype association with delayed AIDS progression in African women</article-title><source>Lancet</source><year>1998</year><volume>351</volume><fpage>1632</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)77688-1</pub-id><pub-id pub-id-type="pmid">9620723</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Anzala A, Ball T, Rostron T, Os&#x02019;Brien S, Plummer F, Rowland-Jones S. CCR2-64I allele and genotype association with delayed AIDS progression in African women. Lancet. 1998;351:1632&#x02013;3. 10.1016/S0140-6736(05)77688-1.<pub-id pub-id-type="pmid">9620723</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Williamson</surname><given-names>C</given-names></name><name><surname>Loubser</surname><given-names>SA</given-names></name><name><surname>Brice</surname><given-names>B</given-names></name><name><surname>Joubert</surname><given-names>G</given-names></name><name><surname>Smit</surname><given-names>T</given-names></name><name><surname>Thomas</surname><given-names>R</given-names></name><etal/></person-group><article-title>Allelic frequencies of host genetic variants influencing susceptibility to HIV-1 infection and disease in South African populations</article-title><source>AIDS</source><year>2000</year><volume>14</volume><fpage>449</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1097/00002030-200003100-00020</pub-id><pub-id pub-id-type="pmid">10770549</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Williamson C, Loubser SA, Brice B, Joubert G, Smit T, Thomas R, et al. Allelic frequencies of host genetic variants influencing susceptibility to HIV-1 infection and disease in South African populations. AIDS. 2000;14:449&#x02013;51. 10.1097/00002030-200003100-00020.<pub-id pub-id-type="pmid">10770549</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Marmor</surname><given-names>M</given-names></name><name><surname>Zhong</surname><given-names>P</given-names></name><name><surname>Ewane</surname><given-names>L</given-names></name><name><surname>Su</surname><given-names>B</given-names></name><name><surname>Nyambi</surname><given-names>P</given-names></name></person-group><article-title>Distribution of CCR2-64I and SDF1-3&#x02032;A alleles and HIV status in 7 ethnic populations of Cameroon</article-title><source>JAIDS J Acquir Immune Defic Syndr</source><year>2005</year><volume>40</volume><fpage>89</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1097/01.qai.0000157008.66584.d6</pub-id><pub-id pub-id-type="pmid">16123688</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Ma L, Marmor M, Zhong P, Ewane L, Su B, Nyambi P. Distribution of CCR2-64I and SDF1-3&#x02032;A alleles and HIV status in 7 ethnic populations of Cameroon. JAIDS J Acquir Immune Defic Syndr. 2005;40:89&#x02013;95. 10.1097/01.qai.0000157008.66584.d6.<pub-id pub-id-type="pmid">16123688</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>H-Z</given-names></name></person-group><article-title>Association between the CCR2-Val64Ile polymorphism and susceptibility to HIV-1 infection: a meta-analysis</article-title><source>Mol Med Rep</source><year>2010</year><pub-id pub-id-type="doi">10.3892/mmr.2010.400</pub-id><pub-id pub-id-type="pmid">21472340</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Zhu H-Z. Association between the CCR2-Val64Ile polymorphism and susceptibility to HIV-1 infection: a meta-analysis. Mol Med Rep. 2010. 10.3892/mmr.2010.400.<pub-id pub-id-type="pmid">21472340</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>B</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>F</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>D</given-names></name><etal/></person-group><article-title>Distribution of two HIV-1&#x02013;Resistant polymorphisms (SDF1-3&#x02032;A and CCR2-64I) in East Asian and world populations and its implication in AIDS epidemiology</article-title><source>Am J Hum Genet</source><year>1999</year><volume>65</volume><fpage>1047</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1086/302568</pub-id><pub-id pub-id-type="pmid">10486323</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Su B, Jin L, Hu F, Xiao J, Luo J, Lu D, et al. Distribution of two HIV-1&#x02013;Resistant polymorphisms (SDF1-3&#x02032;A and CCR2-64I) in East Asian and world populations and its implication in AIDS epidemiology. Am J Hum Genet. 1999;65:1047&#x02013;53. 10.1086/302568.<pub-id pub-id-type="pmid">10486323</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Burastero</surname><given-names>S</given-names></name><name><surname>Casoli</surname><given-names>C</given-names></name><name><surname>Paolucci</surname><given-names>C</given-names></name><name><surname>Breda</surname><given-names>P</given-names></name><name><surname>Alberti</surname><given-names>C</given-names></name><name><surname>Pastori</surname><given-names>C</given-names></name><etal/></person-group><article-title>Anti-CD4-gp120 complex antibodies in long-term non-progressors HIV-1 positive patients: a role in slowing disease progression?</article-title><source>Retrovirology</source><year>2006</year><volume>3</volume><fpage>P36</fpage><pub-id pub-id-type="doi">10.1186/1742-4690-3-S1-P36</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Burastero S, Casoli C, Paolucci C, Breda P, Alberti C, Pastori C, et al. Anti-CD4-gp120 complex antibodies in long-term non-progressors HIV-1 positive patients: a role in slowing disease progression? Retrovirology. 2006;3:P36. 10.1186/1742-4690-3-S1-P36.</mixed-citation></citation-alternatives></ref></ref-list></back></article>